Evidence map›Paper›PMID 24356215›Full record

ArticleAnalytica chimica acta2014

MALDI-target integrated platform for affinity-captured protein digestion.

Asilah Ahmad-Tajudin, Belinda Adler, Simon Ekström, György Marko-Varga, Johan Malm, Hans Lilja, Thomas Laurell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytica chimica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Asilah Ahmad-TajudinDepartment of Measurement Technology and Industrial Electrical Engineering, Lund University, Box 118, 22100 Lund, Sweden; CREATE Health, Lund University, Medicon Village, Bldn 406, 22381 Lund, Sweden; Faculty of Biotechnology and Biomolecular Sciences, University Putra Malaysia, Serdang, Selangor 43400, Malaysia.
Belinda AdlerDepartment of Measurement Technology and Industrial Electrical Engineering, Lund University, Box 118, 22100 Lund, Sweden; CREATE Health, Lund University, Medicon Village, Bldn 406, 22381 Lund, Sweden. Electronic address: Belinda.Adler@elmat.lth.se.
Simon EkströmDepartment of Measurement Technology and Industrial Electrical Engineering, Lund University, Box 118, 22100 Lund, Sweden; CREATE Health, Lund University, Medicon Village, Bldn 406, 22381 Lund, Sweden.
György Marko-VargaDepartment of Measurement Technology and Industrial Electrical Engineering, Lund University, Box 118, 22100 Lund, Sweden.
Johan MalmDepartment of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Skåne University Hospital, 20502 Skåne, Sweden.
Hans LiljaDepartment of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Skåne University Hospital, 20502 Skåne, Sweden; Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Surgery (Urology Service), Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine (GU Oncology Service), Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; Institute of Biomedical Technology, University of Tampere, Tampere 33520, Finland.
Thomas LaurellDepartment of Measurement Technology and Industrial Electrical Engineering, Lund University, Box 118, 22100 Lund, Sweden; CREATE Health, Lund University, Medicon Village, Bldn 406, 22381 Lund, Sweden; Department of Biomedical Engineering, Dongguk University, Seoul, Republic of Korea.

Funding

SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Prospective validation of a multi-marker prostate cancer prediction modelR01CA160816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOORJIAN, STEPHEN, COOPERBERG, MATTHEW R · 2012 to 2015
$1.9M
NCI NIH HHS P50 CA092629NCI NIH HHS P50-CA92629NCI NIH HHS R01 CA160816
6 · The paper itself

Abstract

To address immunocapture of proteins in large cohorts of clinical samples high throughput sample processing is required. Here a method using the proteomic sample platform, ISET (integrated selective enrichment target) that integrates highly specific immunoaffinity capture of protein biomarker, digestion and sample cleanup with a direct interface to mass spectrometry is presented. The robustness of the on-ISET protein digestion protocol was validated by MALDI MS analysis of model proteins, ranging from 40 fmol to 1 pmol per nanovial. On-ISET digestion and MALDI MS/MS analysis of immunoaffinity captured disease-associated biomarker PSA (prostate specific antigen) from human seminal plasma are presented.

Indexed as

Spectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAlkylationAntibodies, MonoclonalChromatography, AffinityHumansMaleOxidation-ReductionProstate-Specific AntigenProteomicsSolid Phase ExtractionAntibodies, MonoclonalProstate-Specific AntigenDigestionImmunoaffinityintegrated selective enrichment targetISETMALDImass spectrometrymatrix-assisted laser desorption/ionizationMRMMSmultiple reaction monitoringprostate specific antigenProteomicsPSAreverse phaseRPsolid-phase extractionSPESPRsurface plasmon resonance

Identifiers

PMID24356215
PMCPMC3935078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.